Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 235 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 Elucidating a Risk of Developing Second Primary Malignancy During and After... August 12, 2021 Load more HOT NEWS 5 Tips for Managing Financial Stress During Cancer FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T... Preoperative ctDNA Levels Are Detectable in the Majority of Patients with...
